base metals investing Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
base metals investing Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
base metals investing First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
base metals investing Real-World Evidence Studies of XPHOZAH® Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
base metals investing Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
base metals investing Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
base metals investing Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® at the American College of Gastroenterology's 2025 Annual Meeting
base metals investing Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week
base metals investing Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
